NGM438

About NGM Biopharmaceuticals

NGM Biopharmaceuticals is a clinical-stage biotech firm focused on discovering and developing first-in-class therapeutics through its integrated biology platform. A key achievement was a major, long-term collaboration with Merck & Co., which provided significant validation and funding, though it was restructured in 2023 to return full rights to NGM for most assets. The company's strategy centers on deeply understanding novel biological pathways, such as GDF15, to address large-market indications with high unmet need, including hyperemesis gravidarum and cancer cachexia. NGM aims to de-risk development through rigorous translational science and patient stratification.

Therapeutic Areas